BALY vs GSK · rev $1.55B vs P/E 13, $103.31B cap
Bally's Corp (BALY) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Bally's Corp (BALY) is a resorts & casinos company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported BALY revenue for 2026-06-30 was $1.55B. Net income was -$308.0M. BALY currently screens at market cap $661.8M.
GSK does not have a complete income-statement cache yet.
BALY currently screens at market cap $661.8M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the BALY and GSK stock pages for the full models.
Not investment advice.